The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Immune gene signatures predict CPR of NSCLC treated with neoadjuvant chemoimmunotherapy
Marta Casarrubios, MSc, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain, talks on an analysis into pre-treatment tumor samples of patients from the Phase II NADIM (NCT03081689) trial undergoing neoadjuvant chemoimmunotherapy. A pro-inflammatory tumor profile in patients with complete pathological response (CPR) was found, dominated by a higher proportion of M1 macrophages. Additionally patients with CPR had a higher expression of pathways associated with lymphocyte infiltrate and antigen presentation. Together, these finding suggest the immune system of patients with CPR was activated prior to immunotherapy compared to non-complete pathological responders. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
